Back to Blog
In a recent study published in The New England Journal of Medicine, Dr. Andre Kalil (University of Nebraska Medical Center) and colleagues administered a combination of two drugs: remdesivir and baricitinib to 515 patients hospitalized with moderate or severe COVID-19 symptoms. The control group consisting of 518 patients, received the drug remdesivir and a placebo. The patients who received the combination of both drugs recovered one day earlier than the control group. The mortality rate was also lower in the group that received both drugs (5.1%) compared to the control group (7.8%) that received remedesivir alone.
The recovery time was further reduced in patients who were receiving non-invasive ventilation at the time of drug treatment. In these patients, median recovery time took 10 days compared to control group, where it took 18 days. The combination of remdesivir and baricitinib performed far superior to remdesivir alone, especially in patients who are on non-invasive ventilation.